VIA

Vaccination In Atherosclerosis

Coordinatore	UNIVERSITEIT LEIDEN    more  Organization address address: RAPENBURG 70 city: LEIDEN postcode: 2300 RA contact info Titolo: Mr. Nome: Ton Cognome: Brouwer Email: send email Telefono: +31 71 5273149 Fax: +31 71 5275269
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	8˙136˙785 €
EC contributo	5˙994˙233 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-12-01   -   2018-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITEIT LEIDEN  Organization address address: RAPENBURG 70 city: LEIDEN postcode: 2300 RA contact info Titolo: Mr. Nome: Ton Cognome: Brouwer Email: send email Telefono: +31 71 5273149 Fax: +31 71 5275269	NL (LEIDEN)	coordinator	1˙158˙815.50
2	STICHTING CENTRE FOR HUMAN DRUG RESEARCH  Organization address address: ZERNIKEDREEF 10 city: LEIDEN postcode: 2333 CL contact info Titolo: Prof. Nome: Koos Cognome: Burggraaf Email: send email Telefono: +31 715246400 Fax: +31 715246499	NL (LEIDEN)	participant	731˙000.20
3	LUNDS UNIVERSITET  Organization address address: Paradisgatan 5c city: LUND postcode: 22100 contact info Titolo: Dr. Nome: Jacqueline Cognome: Postma Email: send email Telefono: +46 40 39 12 36 Fax: +46 40 39 12 22	SE (LUND)	participant	640˙000.00
4	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Mrs. Nome: Caroline Cognome: Hamilton Email: send email Telefono: 46851775959	SE (STOCKHOLM)	participant	565˙001.00
5	CARDIOVAX LLC  Organization address address: GLENBARR AVENUE 10345 city: LOS ANGELES CA postcode: 90064 contact info Titolo: Dr. Nome: Mark Cognome: Carvlin Email: send email Telefono: +1 6095145300 Fax: +1 6095145301	US (LOS ANGELES CA)	participant	527˙500.00
6	GOETEBORGS UNIVERSITET  Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 contact info Titolo: Dr. Nome: Ellen Cognome: Rydberg Email: send email Telefono: +46 31 786 6470 Fax: +46 31 786 4355	SE (GOETEBORG)	participant	452˙550.00
7	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Ms. Nome: Renata Cognome: Schaeffer Email: send email Telefono: +441223 333543 Fax: +44 1223 332988	UK (CAMBRIDGE)	participant	452˙500.00
8	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Dr. Nome: Giuseppina Cognome: Caligiuri Email: send email Telefono: +33 140257556 Fax: +33 140258602	FR (PARIS)	participant	452˙254.00
9	MEDIZINISCHE UNIVERSITAET WIEN  Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Christoph Cognome: Binder Email: send email Telefono: +43 1 40400 73755 Fax: +43 1 40400 73588	AT (WIEN)	participant	451˙972.00
10	BRENNTAG NORDIC AS/BRENNTAG BIOSECTOR AS  Organization address address: STRANDVEJEN 104 A city: HELLERUP postcode: 2900 contact info Titolo: Mr. Nome: Jan Cognome: Olesen Email: send email Telefono: +45 43292835	DK (HELLERUP)	participant	302˙340.00
11	PROBIOGEN AG  Organization address address: Goethestrasse 54 city: Berlin postcode: 13086 contact info Titolo: Mrs. Nome: Andrea Cognome: Hauptmann Email: send email Telefono: +49 30924006148 Fax: +49 3092400619	DE (Berlin)	participant	254˙380.00
12	POLYGENE AG	CH	participant	5˙920.03

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%). In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU. Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underlying pathology of CVD and atherosclerosis is responsible for 70% of all cases of CVD. Extensive studies into the pathology of atherosclerosis show that its etiology is found in a combination of dyslipidemia and a related inflammatory response with an established autoimmune component, while the major cause of acute CVD events, plaque rupture, due to an inflammatory destabilization of the atherosclerotic lesion. CVD is therefore an autoimmune-like disease in the context of a metabolic disease. Thus far, therapeutic approaches in CVD have been focused at normalizing dyslipidemia in order to lower plasma cholesterol. Statins and additional surgical approaches such as angioplasty have achieved a 30% risk reduction for CVD during the last 10-15 years. However, additional approaches to improve the treatment of dyslipidemia by for instance improving the level of the anti-atherogenic lipoprotein HDL have failed in a number of clinical trials. This implicates that new therapeutic approaches are urgently needed to narrow down the remaining 70% risk for CVD. We aim to develop a new immunomodulatory treatment, a therapeutic vaccine that permanently restores the immune balance within the arterial wall by inhibiting the inflammatory responses during atherosclerosis. The VIA consortium aims to develop a vaccine, dissect the immune pathways underlying the beneficial effect of the vaccine, optimize the vaccine, test its safety and perform a phase I clinical trial using the atheroprotective vaccine. The vaccine is foreseen to result in a substantial lowering of the risk for CVD.'